SELLAS Life Sciences Group Inc SLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLS is a good fit for your portfolio.
News
-
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
-
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
-
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
-
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
-
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
-
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
-
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
-
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
Trading Information
- Previous Close Price
- $1.54
- Day Range
- $1.46–1.72
- 52-Week Range
- $0.50–1.91
- Bid/Ask
- $1.62 / $1.63
- Market Cap
- $91.15 Mil
- Volume/Avg
- 2.0 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
Valuation
|
Metric
|
SLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLS
Financial Strength
|
Metric
|
SLS
|
|---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.23 |
Interest Coverage | — |
Quick Ratio
SLS
Profitability
|
Metric
|
SLS
|
|---|---|
Return on Assets (Normalized) | −212.56% |
Return on Equity (Normalized) | −1,593.58% |
Return on Invested Capital (Normalized) | −1,180.46% |
Return on Assets
SLS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bztdtzmkp | Ftg | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zhchcsz | Rxsnd | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dzwfwxr | Qksdp | $98.8 Bil | |
MRNA
| Moderna Inc | Brwxddh | Fhr | $38.8 Bil | |
ARGX
| argenx SE ADR | Xhjrcrdb | Zxmtn | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Fmtybbcxw | Qnmfq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Msyddbwrj | Dtlql | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rhmtjghd | Kpksx | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Znsmvnwspr | Ndpwz | $12.4 Bil | |
INCY
| Incyte Corp | Mtfkjcgf | Vtdpvfz | $11.9 Bil |